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Many uncontrolled studies and a subsequent meta-analysis
suggest that hemolytic uremic syndrome (HUS) with a
positive history for diarrhea is associated with a significant
increase in chronic renal disease. Two recent controlled
studies that followed children with this type of HUS after
Escherichia coli O157:H7 outbreaks, and where the controls
were selected from a group exposed in the outbreak, gave
conflicting results. To clarify this apparent difference, we
retrospectively compared a cohort of 30 children with
sporadic diarrhea-positive HUS with 30 healthy controls
who had no history of bloody diarrhea or HUS and who
had similar age and gender. Significantly more children with
previous HUS than the controls had albuminuria over a
median follow-up of 6.2 years. Of these albuminuric patients,
one-third had macroalbuminuria compared with none of the
controls. Following HUS, children were three times more
prone to hypertension and prehypertension, although the
difference was not statistically significant. Glomerular
filtration rates, estimated by cystatin C, were significantly
lower by 30ml/min/1.73m2. Thus, children with sporadic HUS
with positive history of diarrhea compared with unexposed
controls had a higher prevalence of chronic renal disease;
results consistent with the meta-analysis. Prospective studies
with appropriate controls are needed to completely resolve
this issue.
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Diarrhea-positive hemolytic uremic syndrome (Dþ HUS) is
a major cause of acute kidney injury in children.1,2 Similar to
other acute renal injuries, a HUS episode has the potential
to decrease nephron endowment initially with subsequent
increase in proteinuria, hypertension, and impaired glome-
rular filtration rate (GFR).3 A clear understanding of the
risk of these chronic renal sequelae is important to guide the
long-term follow-up after a HUS episode.
Chronic renal sequelae after Dþ HUS have been the
subject of considerable debate. Some studies have reported
minimal renal sequelae after Dþ HUS.4–6 However, most
studies have found an increase in proteinuria, hypertension,
and impaired GFR after Dþ HUS.7–20 A meta-analysis based
on these studies estimated chronic renal abnormalities
(hypertension, overt proteinuria, GFR o80ml/min/1.73m2)
in a quarter of children after an average follow-up of 4 years.21
A major limitation of the studies in the meta-analysis is a
lack of matched controls. This is an important consideration
as inclusion of a control arm will reduce misestimating the risk
of renal sequelae by controlling for unrelated asymptomatic
proteinuria, prehypertension, and hypertension, which
increase with the increase in obesity in otherwise healthy
children.22–24
To highlight this point further, a recent prospective study
on Dþ HUS after an E. coli O157:H7 outbreak with a
matched control arm did not find a higher prevalence of
overt proteinuria, hypertension, and chronic kidney disease
in children after Dþ HUS.25 The results of this study
suggested the possibility of an inflated estimate of chronic
renal sequelae in the meta-analysis because the uncontrolled
design of the included studies.21 As the controls in this
controlled study were exposed to E. coli O157:H7 during the
outbreak, it is also possible that unrecognized subclinical
renal injury in controls from the exposure of shiga toxin26–28
or by the inclusion of subjects with undetected incomplete
HUS in the control group29,30 could have masked the
difference in renal abnormalities in the HUS patients versus
their controls. Also, a further masking in the difference
is possible due to the attenuation of acute renal injury in
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Dþ HUS during an outbreak, by an early diagnosis, and by
prompt fluid therapy.31
On the basis of these assumptions, we hypothesized that
renal outcome after an outbreak of Dþ HUS assessed with
exposed controls could be less severe than that after sporadic
Dþ HUS with unexposed controls. To test our hypothesis,
we assessed the long-term renal sequelae of children, who had
previous sporadic Dþ HUS, and compared their outcomes
with age and gender-matched healthy controls who had not
knowingly been exposed to an E. coli O157:H7 outbreak.
RESULTS
Screening for the study cohort
In all, 52 subjects with previous Dþ HUS satisfying our
inclusion criteria were identified from the records. A total of
22 could not be enrolled (15 not tracked, 1 moved out of
province, and 6 did not consent). In those not enrolled,
median age at the time of HUS episode was 3.4 years (range
7 months–16 years), and 20 (91%) of them aged below 12
years had HUS. In all, 15 (58%) were females; 18 (81%) had
an E. coli documentation on stool culture, and 11 (50%)
required dialysis initially. Finally, 30 subjects constituted
the HUS group and were compared with 30 age and gender-
matched healthy controls.
Demographics of HUS patients and controls
The HUS patients and controls were matched for age
(median 9 years; range 3–26) and gender (female 53%) as
per the study design. These two groups were comparable with
regard to body mass index (BMI) z-scores (P¼ 0.93), and the
proportion of underweight (P¼ 0.90), overweight (P¼ 0.54),
and obese (P¼ 0.29) subjects (Table 1).
In the HUS group, median age at the time of HUS episode
was 2.5 years (range 3 months–15.3 years). In all, 29 (97%)
had HUS below 12 years of age and 16 (53%) required a
short-term dialysis initially. None of them required dialysis
after the initial recovery. A total of 24 (80%) patients were
stool culture or verotoxin-positive. Median follow-up was
6.2 years (range 3.3–20.1).
Chronic renal sequelae in the HUS patients and controls
The HUS subjects and controls were compared for albumi-
nuria, systolic and diastolic blood pressure (BP) z-scores, and
estimated GFR (eGFR) by cystatin C and creatinine formulae
(Table 2). The HUS subjects had a markedly higher urine
albumin to creatinine ratio (median and 95% confidence
interval, 2.70 (3.42, 17.25) versus 0.60 (0.72, 1.60), P¼ 0.001)
(Figure 1). In all, 40% of the HUS patients showed
albuminuria in contrast to only 3% of controls (relative risk
12; P¼ 0.001). One-third of HUS subjects with albuminuria
had macroalbuminuria, whereas none of the control subjects
had macroalbuminuria. The HUS group had a lower cystatin
C eGFR (30ml/min/1.73m2; P¼ 0.001) and creatinine eGFR
(20ml/min/1.73m2; P¼ 0.02) than controls. There was a
trend towards higher BP after HUS (three times more
hypertension and prehypertension, and a higher systolic and
diastolic BP in HUS subjects), although the difference did
not reach statistical significance. This may be because of five
HUS subjects on angiotensin converting enzyme inhibitors
(three for albuminuria and two for hypertension) versus
none in controls (Table 2).
Comparison of the HUS patients with different follow-up
durations
The HUS patients with shorter follow-up (o5 years) were
compared with those with a follow-up of X5 years. Age at
the time of HUS and initial dialysis requirement were similar
in the two groups (Table 3). Both groups did not differ in
their urine albumin to creatinine ratio, BP z-scores, eGFR,
and subjects with albuminuria, hypertension, prehyperten-
sion, and angiotensin converting enzyme inhibitor therapy.
Comparison of the enrolled HUS subjects with those not
enrolled
We analyzed the impact of non-enrollment on our results.
Previous studies have shown that a randomly missed follow-up,
rather than a systematic missing pattern, does not impact the
applicability of results.32–34 Absence of consent, despite
awareness with regard to the study, in only 6/22 non-enrolled
HUS subjects did not suggest a systematic pattern.32 A
random pattern of the missing data was also confirmed
by two suggested techniques: first, by establishing similar
characteristics of those enrolled and not enrolled (age
(P¼ 0.20), gender distribution (P¼ 0.30), E. coli documen-
tation (P¼ 0.40), and dialysis requirement (P¼ 0.50)), and
second, by predictive logistic regression by creating a dummy
dependent variable (enrolled¼ 1, non-enrolled¼ 0).33,34 We
Table 1 | Characteristics of patients with previous HUS and
the matched controls
HUS patients
(n=30)
Controls
(n=30) P-value
Median age; range (year) 9.0; 3, 26 9.0; 3, 26 NS
Age distribution (years)
o12 19 (63.3%) 19 (63.3%)
12–18 5 (16.6%) 5 (16.6%)
418 6 (20.0%) 6 (20.0%)
Female (%) 16 (53.3) 16 (53.3) NS
Family history of kidney
disease (%)
3 (10.0) 1 (3.3) 0.61
Previous dialysis (%) 16 (53.3) —
BMI z-scorea 0.87±1.71 0.83±1.79 0.93
BMI percentilea 66.84±30.61 64.07±36.08 0.77
BMI 22.09±1.72 24.36±4.37 0.28
Underweight (%) 1 (3.3) 3 (10) 0.90
Overweight (%) 4 (13.3) 3 (10) 0.54
Obese (%) 7 (23.3) 9 (30) 0.29
Abbreviations: BMI, body mass index; HUS, hemolytic uremic syndrome; NS, not
significant.
az-scores and percentiles of BMI are reported for those aged below 18 years. For
those who are 18 years and older, absolute values of BMI are stated.
Data are expressed as mean±s.d., unless stated otherwise.
For o18 years, underweight: o5th percentile; normal weight: 5th–85th percentiles;
overweight: 85th–95th percentiles; and obese: X95th percentile.43 For X18 years,
underweight: o18.5; normal: 18.5–24.9; overweight: 25–29.9; and obese X30.
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did additional analysis by extrapolating the proportion of
albuminuria (3%), prehypertension, and hypertension (10%)
from the enrolled control group (n¼ 30) to non-enrolled
HUS subjects (n¼ 22) and to additional 22 controls. The
difference in the extrapolated groups (n¼ 52, each) still
showed significant difference in albuminuria (P¼ 0.003);
however, the difference in prehypertension and hypertension
did not reach statistical significance (P¼ 0.17), which was
similar to the results of enrolled HUS subjects and controls
(P¼ 0.10). To assess a sample-size effect, we did similar
extrapolation based on albuminuria (40%), prehypertension,
and hypertension (30%) in the enrolled HUS group (n¼ 30)
to those not enrolled (n¼ 22), and by extrapolating
corresponding proportions (3 and 10%) from the enrolled
controls (n¼ 30) to additional 22 controls. In these
extrapolated groups (n¼ 52, each), albuminuria was expect-
edly significantly different (Po0.001); however, the differ-
ence in prehypertension and hypertension also reached
statistical significance (P¼ 0.01).
DISCUSSION
Two controlled studies following children after E. coli
outbreaks25,35 failed to confirm the opinion, on the basis of
previous uncontrolled studies and a large meta-analysis,7–20
that Dþ HUS induces a major increase in long-term renal
sequelae. Concern about these conflicting observations led us
to investigate the patients with sporadic Dþ HUS, with
healthy controls not knowingly exposed to an E. coli O157:H7
outbreak.
In the initial controlled study, Ogborn et al.35 compared
18 children who had Dþ HUS in an E. coli O157:H7
outbreak with 18 exposed controls. After a 4-year follow-up,
both HUS and control groups remained comparable with
respect to systolic and diastolic BP, proteinuria, and
creatinine-based eGFR but HUS survivors had a higher
prevalence of hematuria. This study suggested that E. coli
HUS, in the setting of an outbreak, does not increase chronic
renal sequelae. The interpretation of this study was limited by
not reporting BP z-scores or percentiles, to account for the
Table 2 | Renal parameters in patients with previous HUS and the matched controls
HUS patients (n=30) Controls (n=30) P-value
Systolic BP z-score; median (95%CI)a 0.25 (0.52, 0.36) 0.07 (1.22, 0.46) 0.65
Systolic BP percentilea 48.31±32.0 46.18±24.05 0.82
Systolic BP (mmHg) 120.85±11.96 112.66±9.13 0.21
Diastolic BP z-score; median (95%CI)a 0.31 (0.03, 0.65) 0.57 (1.66, 0.51) 0.09
Diastolic BP percentilea 58.44±24.98 48.43±26.31 0.17
Diastolic BP (mmHg) 73.66±9.72 64.16±7.33 0.08
Hypertension and prehypertension (%) 9 (30) 3 (10) 0.10
Hypertension (%) 2 (6.6) 0
Prehypertension (%) 7 (23.3) 3 (10)
Albumin/creatinine (mg/mmol); median (95%CI) 2.70 (3.42, 17.25) 0.60 (0.72, 1.60) 0.001
Albuminuria (%) 12 (40) 1 (3.3) 0.001
Microalbuminuria (%) 8 (26.6) 1 (3.3)
Macroalbuminuria (%) 4 (13.3) 0
Medications for blood pressure or albuminuria (%)b 5 (16.6) 0
Creatinine-based eGFR 117.84±33.08 140.88±41.45 0.02
Cystatin C (mg/l) 0.76±0.20 0.62±0.09 0.002
Cystatin C-based eGFR 131.60±32.17 159.67±28.32 0.001
Abbreviations: BP, blood pressure; CI, confidence interval; eGFR, estimated GFR (ml/min/1.73m2); HUS, hemolytic uremic syndrome.
To convert urine albumin to creatinine ratio from mg/mmol to mg/g, multiply by 8.84; to convert GFR from ml/min/1.73m2 to ml/s/1.73m2, multiply by 0.01667.
az-scores and percentiles of BP are reported for those aged below 18 years. For 18 years and older subjects, absolute values of BP are stated. For o18 years, BP levels were
classified according to the fourth report (prehypertension: 90th and 95th percentile or in adolescents BPX120/80 even if BP o90th percentile; hypertension: BP 495th
percentile or antihypertensive medication already initiated for a diagnosed hypertension).51 For X18 years, BP was categorized according to the seventh JNC report
(prehypertension: 120–139/80–89; hypertension: X140/90).52
bEnalapril, for albuminuria in three and for hypertension in two subjects.
Data are expressed as mean±s.d., unless stated otherwise.
Microalbuminuria was defined as urine albumin/creatinine ratio of 3.4mg/mmol (30mg/g) to 33.9mg/mmol (300mg/g), and macroalbuminuria as urine albumin/creatinine
ratio 433.9mg/mmol (300mg/g).
Creatinine-based GFR was estimated by the Schwartz formula48 in children and adolescents aged below 18 years, and by the modified diet in renal disease (MDRD) equation49
in 18 years or older subjects.
Cystatin C-based estimated GFR was estimated by the Filler formula.39
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Figure 1 |Urine microalbumin to creatinine ratio (mg/mmol)
in HUS patients (subjects with hemolytic uremic syndrome
in the past) and controls (matched controls).
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age dependency of BP. Also proteinuria quantification was
performed by dipstick only. The controlled study by Garg
et al.25 reported 5-year follow-up of 19 children with Dþ
HUS in an E. coli outbreak. This study found a comparable
BP and macroalbuminuria in the HUS group and controls;
however, more children with HUS had microalbuminuria,
and cystatin C eGFR was 10ml/min/1.73 m2 lower in the
HUS group. This study had the methodological strengths of
an adequate statistical power, a control arm, urinary albumin
quantification, and GFR estimation by cystatin C. Both
studies were similar in their selection of controls from the
outbreak-exposed population, which may introduce a
potential contamination from subclinical renal damage27,28
or by the inclusion of cases with incomplete HUS29,30 in the
control arm. In relative terms, Garg et al.25 had a lower risk
of contamination as their controls were asymptomatic,
whereas the controls in the study by Ogborn et al.35 had
gastroenteritis.
When compared with these two controlled studies,25,35
our HUS group showed more renal sequelae than controls.
However, these renal sequelae were still lower than that
estimated by meta-analysis on the basis of previous
uncontrolled studies.7–21 Subjects with albuminuria were
double in our HUS group than in study by Garg et al.25
Macroalbuminuria was present in one-third of our HUS
subjects with albuminuria as compared with none from the
Garg’s study.25 When compared with respective controls,
cystatin C eGFR was three times lower and the prevalence of
hypertension and prehypertension was three times higher in
our HUS subjects than that observed by Garg et al.25
Angiotensin converting enzyme inhibitor prescription was
five times more in our HUS subjects than in the study by
Garg et al.25
Despite the similarity of controlled designs, a higher
prevalence of chronic renal sequelae in our analysis as
compared with other two controlled studies made us look at
the possible reasons.25,35 Similar distribution of overweight
and obese subjects in our HUS patients and controls
accounted for a possible confounding from obesity-
associated albuminuria, prehypertension, and hyper-
tension.23,24 The z-scores of weight and height35 and also
BMI25 were comparable between the HUS and control groups
in other controlled studies. E. coli documentation in 80% of
our HUS subjects was similar to 84% confirmed cases
reported by Garg et al.25 Recent evidence suggests a strain-
specific variation in E. coli O157:H7 virulence,36 which may
affect the severity of acute renal injury. In the absence of
strain recognition in our study and other studies,25,35 we
cannot comment on a possible impact of E. coli virulence on
the results. This issue needs consideration in future studies.
Although our median follow-up of 6.2 years was somewhat
longer than 4- and 5-year follow-up in other studies,25,35 our
Table 3 | Renal parameters in patients with previous HUS with a follow-up o5 years and X5 years
Follow-up o5 years (n=12) Follow-up X5 years (n=18) P-value
Median age at the time of HUS; range (year) 2.75; 0.70, 15.30 2.25; 0.30, 11.50 0.58
Female (%) 4 (33%) 12 (66%) 0.07
Dialysis (%) 6 (50%) 10 (55%) 0.70
Systolic BP z-scorea median (95%CI) 0.25 (0.75, 0.67) 0.35 (0.76, 0.52) 0.86
Systolic BP percentilea 47.08±33.34 45.55±32.07 0.91
Systolic BP (mmHg) — 120.85±10.14
Diastolic BP z-scorea median (95%CI) 0.30 (0.20, 0.89) 0.19 (0.23, 0.79) 0.84
Diastolic BP percentilea 34.08±32.92 18.75±29.96 0.24
Diastolic BP (mmHg) — 73.66±8.46
Hypertension and prehypertension (%) 4 (34%) 5 (28%) 0.18
Hypertension (%) 2 (17%) 0
Prehypertension (%) 2 (17%) 5 (28%)
Albumin/creatinine (mg/mmol) median (95%CI) 2.90 (0.30, 20.44) 1.60 (0.50, 20.50) 0.95
Albuminuria (%) 5 (42%) 7 (39%) 0.86
Microalbuminuria (%) 3 (25%) 5 (28%)
Macroalbuminuria (%) 2 (17%) 2 (11%)
Medications for blood pressure or albuminuriab (%) 3 (25%) 2 (11%) 0.30
Creatinine-based eGFR 125.69±25.07 113.04±36.98 0.32
Cystatin C (mg/l) 0.76±0.27 0.76±0.14 0.95
Cystatin C-based eGFR 137.06±43.07 129.04±23.08 0.47
Abbreviations: BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate (ml/min/1.73m2); HUS, hemolytic uremic syndrome.
az-scores and percentiles of BP are reported for those aged below 18 years. For 18 years and older subjects, absolute values of BP are stated. For o18 years, BP levels were
classified according to the fourth report (prehypertension: 90th and 95th percentile or in adolescents BPX120/80 even if BP o90th percentile; hypertension: BP 495th
percentile or antihypertensive medication already initiated for a diagnosed hypertension).51 For X18 years, BP was categorized according to the seventh JNC report
(prehypertension: 120–139/80–89; hypertension: X140/90).52
bEnalapril, for albuminuria in three and for hypertension in two subjects.
Data are expressed as mean±s.d., unless stated otherwise.
Microalbuminuria was defined as urine albumin/creatinine ratio of 3.4mg/mmol (30mg/g) to 33.9mg/mmol (300mg/g), and macroalbuminuria as urine albumin/creatinine
ratio 433.9mg/mmol (300mg/g).
Creatinine-based GFR was estimated by the Schwartz formula48 in children and adolescents aged below 18 years, and by the modified diet in renal disease (MDRD) equation49
in 18 years or older subjects.
Cystatin C-based estimated GFR was estimated by the Filler formula.
To convert urine albumin to creatinine ratio from mg/mmol to mg/g, multiply by 8.84; to convert GFR from ml/min/1.73m2 to ml/s/1.73m2, multiply by 0.01667.
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HUS subjects with 5-year or longer follow-up did not have a
higher albuminuria, BP z-scores, and eGFR than those with
shorter follow-up. Other studies have also observed protei-
nuria and decreased GFR within the first few years in the
majority of Dþ HUS survivors who manifest chronic renal
sequelae.4,12,37
It is also important to understand that Dþ HUS is not a
uniform disease and a severe acute renal injury predicts
higher long-term renal sequelae.10,12 We argue that sporadic
setting versus outbreak exposure can affect the severity of
HUS. Also, the assessment of chronic renal sequelae may vary
if the control arm is exposed to an outbreak. Our hypothesis
is based on the previous work by Ake et al.31 reporting the
attenuation of renal injury by an early recognition of E. coli
O157:H7 infections and parenteral volume expansion before
the development of HUS. An outbreak setting offers the
advantage of prompt recognition of new cases and lesser
delay in the delivery of medical care. A water-borne origin of
E. coli in some outbreaks,25,35 rather than a food source,
could also dilute the inoculum resulting in a lesser shiga toxin
exposure and potentially milder initial renal injury.
Conversely, sporadic Dþ HUS may have a longer time lag
in the diagnosis and a larger inoculum in many cases due to
food-borne contamination, which may result in greater initial
renal injury. Our data supported this hypothesis as our HUS
group had greater acute renal injury suggested by a higher
initial dialysis need (53%) than in other two outbreak studies
(2235 and 37%25). Our reasoning of a higher probability
of undiagnosed renal injury in controls selected from an
outbreak-exposed population is based on in vivo evidence of
subclinical renal injury from the exposure to E. coli O157:H7
shiga toxin,26–28 and clinical studies reporting incomplete
HUS not requiring medical attention.29,30 Our data sup-
ported the risk of renal injury in exposed controls, as the
exposed controls enrolled by Garg et al.25 had about one and
a half times higher urine microalbumin to creatinine ratio
and BP percentiles, 5% controls with hypertension (none in
our controls), and 30% lower cystatin C eGFR than our
unexposed controls. The risk of long-term renal sequelae
simply from E. coli exposure even without HUS was
suggested by a higher prevalence of hypertension and reduced
GFR in 1985 adults followed for 4 years after a self-limited
E. coli O157:H7 gastroenteritis.38
Extrapolating these findings about exposure, the lack of
difference in chronic renal sequelae between the HUS
patients and controls in the study by Ogborn et al.35 could
be due to milder acute renal injury in their HUS patients
because of an outbreak setting, and greater undetected renal
injury in the exposed controls as they had diarrhea. Despite
an outbreak setting, no diarrhea in the controls of Garg
et al.21,24,25,38 suggests a lower risk of subclinical renal injury
in the exposed controls, and therefore, a trend towards higher
renal sequelae than in the study by Ogborn et al.35 In our
study, the combination of a sporadic setting (more chronic
sequelae from greater acute renal injury) and lack of exposure
to an outbreak (absence of subclinical renal injury in the
controls) can explain the higher chronic renal sequelae than
that reported by Ogborn et al.35 and Garg et al.21,24,25,38 Our
lower chronic renal sequelae, than in previous uncontrolled
studies, and the meta-analysis7–21 could be because of the
inclusion of a control arm that accounted for unrelated
proteinuria, prehypertension, and hypertension in the
general population.22–24
Selection of HUS patients from a hospital database exposes
our study to referral bias. However, referral bias may not be
significant given that we remained the sole referral center for
our designated geographical area, and the prevalent practice
warranted a referral to the pediatric nephrology service for
HUS. Our screening of database for HUS rather than for renal
failure secondary to HUS lowered the bias towards including
more cases with severe renal injury. Similar to missed follow-
up in other studies that was around 30% in study by Garg
et al.,25 we could not enroll 42% of initially identified HUS
subjects, which can be partly because of our study design and
a longer follow-up. Missed follow-up may induce a wellness
or sickness bias. However, the analysis of our missed follow-
up suggested a random rather than a systematic pattern,
which has been shown to maintain the validity of observa-
tions.32 Further, extrapolation based on controls to non-
enrolled HUS subjects still showed a significant difference in
albuminuria between the HUS group and controls. Similar
extrapolation for prehypertension and hypertension repli-
cated the trend of higher prehypertension and hypertension
without reaching the statistical significance seen in enrolled
HUS subjects. Although our enrolled sample provided
adequate statistical power to detect a clinically meaningful
difference in renal sequelae between the HUS subjects and
controls, extrapolation analysis based on renal sequelae in the
HUS group to non-enrolled HUS subjects suggested the
possibility of picking a bigger difference in renal sequelae with
a larger study sample. A treatment bias seems unlikely, as the
policy of supportive care for Dþ HUS remained consistent
throughout the period.
The strengths of our study are the inclusion of a matched
healthy control arm, urine albumin quantification, eGFR
estimation by cystatin C, and accounting for age and gender-
dependency of body mass and BP by calculating the
respective percentiles and z-scores. Estimation of chronic
renal sequelae after Dþ HUS with matched unexposed
control arm is reported for the first time in our analysis. This
is an important issue considering a high prevalence of
asymptomatic unrelated derangement of renal parameters
in pediatric population, which increase with obesity
epidemic,22–24 and possibility of asymptomatic renal impair-
ment in controls from the exposure of shiga toxin in
outbreaks.19,27,29,30,38 Despite the fact that microalbuminuria
may be the first marker of renal injury, albumin quantifica-
tion after HUS has been done in only a few studies.9,25
Although nuclear GFR would have provided a better estimate
of kidney functions, its application in healthy controls was
not practical. Cystatin C is believed to be a better marker of
GFR estimation than serum creatinine.39–41
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In summary, our retrospective cohort-matched analysis of
sporadic Dþ HUS survivors using healthy controls reveals a
high risk of developing chronic renal sequelae in the follow-up.
This observation is different from that in controlled studies
after E. coli O157:H7 outbreaks, with symptomatic and
asymptomatic exposed controls.25,35 Prospective studies with
appropriate controls are needed to completely resolve this
issue.
MATERIALS AND METHODS
Study setting and participants
This retrospective cohort-matched study was approved by the
University of Western Ontario Research Ethics Board, with written
informed consents obtained from the parent/guardian or partici-
pants, in cases older than 18 years, before study enrollment.
Electronic medical records were screened from the period 1988 to
2005 for children admitted with the diagnosis of HUS. The findings
of HUS were verified. An established HUS episode with a
documented preceding diarrhea was labeled as Dþ HUS. Presence
of non-bloody diarrhea was not an exclusion criterion.42 Exclusion
criteria were a Dþ HUS from an outbreak, a diagnosis of atypical
HUS or use of plasma therapy (suspicion of thrombotic thrombo-
cytopenic purpura). Details on demographic data and dialysis need
were extracted. Letters were sent to the identified patients explaining
the rationale of the study, with phone call follow-up to expand on
the provided information and to answer related questions. Those
not located by letter or phone call were tracked by calling the family
doctor or the family member recorded in their hospital record.
Those enrolled in the study underwent a standardized BP check-up,
weight and height recording, and blood and urine testing.
Healthy controls were age and gender-matched for enrolled HUS
subjects, selected from subjects requiring blood work not expected
to affect study parameters e.g. pre-surgery screening for minor
elective surgery. Healthy status of controls was carefully ensured by
excluding any chronic disease including diabetes and hypertension,
no previous history of bloody diarrhea and/or HUS, or acute renal
issue and a recent acute illness. The controls underwent BP, weight,
height recording and blood testing according to the same protocol as
for the HUS patients.
Measurements of BMI, renal function, and BP
Weight and height were recorded on a calibrated digital scale and
stadiometer (Holton, Crymatch, UK). BMI was calculated as height/
weight squared (kg/m2). In children and adolescents aged below 18
years, BMI z-scores and BMI percentile were calculated using the
2000 Centers for Disease Control and Prevention growth charts
(underweight:o5th percentile; normal weight: 5th–85th percentiles;
overweight: 85th–95th percentiles; obese: X95th percentile).43 In
18-year and older subjects, body weight was categorized according
to absolute BMI (underweight: o18.5; normal:18.5–24.9; over-
weight: 25–29.9; obese X30).
Urine albumin level was measured using the Image Beckman
Coulter immunoassay (Beckman Coulter, Fullerton, CA, USA).
Microalbuminuria was defined as a urine albumin/creatinine ratio
of 30–300mg/g (3.4–33.9mg/mmol).22,44–46 In subjects aged below
18 years, creatinine-based eGFR was estimated by using the Schwartz
formula;47 GFR¼ k (height (cm)/serum creatinine (mmol/l)).
Recalibrated k constants for the formula were used for a better
estimate: for males aged 2–13 years and all females, k was 0.523; and
for males aged 13–18 years, k was 0.564.48 In 18 years or older
subjects, creatinine-based eGFR was estimated by the modified diet in
renal disease equation;49 GFR (ml/min/1.73m2)¼ 186 (Scr)1.154
(age)0.203 (0.742 if female) (1.212 if African–American)
(conventional units). In addition, eGFR was assessed by serum
cystatin C level;39 GFR: log(GFR)¼ 1.962þ (1.123 log(1/cystatin
C)). The cystatin C equation is independent of age, sex, and body
mass, and is considered to be more reliable than creatinine-based
eGFR.39,41,50 In the present study, cystatin C was measured in the
same laboratory at which this equation was derived.39
Casual BP was measured in supine position after 10min rest. The
cuff covered two-third length of the upper arm, with the bladder
covering the arm circumference. An average of three BP measure-
ments, recorded at 2-min intervals, with the standard oscillometric
method (Dynamap; Critikon, Tampa, FL, USA) was used for the
analysis. For children and adolescents, BP measurements were
converted to z-scores and percentiles on the basis of age, sex, and
height,51 and BP levels were classified according to the fourth report
(prehypertension: 90th–95th percentile or in adolescents BP X120/
80 even if BP o90th percentile; hypertension: BP 495th percentile
or antihypertensive medication already initiated).51 In 18-year or
older subjects, BP was categorized according to the seventh JNC
report (prehypertension: 120–139/80–89; hypertension: X140/90).52
Statistical analysis
Continuous data were tested for normal distribution using the
Shapiro–Wilks test. Categorical data were compared using Fisher
exact test. Normally distributed data were analyzed using parametric
methods (mean, s.d., and t-test). When data were not distributed
normally, non-parametric methods (median, range, 95% confidence
interval, and Wilcoxon rank–sum test) were used. Two-tailed P-value
o0.05 was considered significant. On the basis of variance estimate,
our data had 80% statistical power to detect a difference of
9mg/mmol in urine albumin to creatinine ratio, 20ml/min/1.73m2
for cystatin C eGFR, 9mmHg for systolic BP, and 7mmHg for
diastolic BP. We used SPSS version 17 (SPSS, Chicago, IL, USA) for
the statistical analysis.
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